Vistagen announced that it has been granted patents related to the use of PH80 pherine nasal spray for the treatment of migraine in Australia, Hong Kong, Japan, and Mexico. All four of the new patents should cover PH80 through 2040. The USPTO granted a patent covering the use of PH80 for migraine in 2022, and the EPO followed in 2023.
PH80 intranasal epoxyestrenolone is currently in Phase 2 development for the treatment of hot flashes in menopausal women. Vistagen acquired PH80, along with PH10 and PH94B nasal sprays when it acquired Pherin Pharmaceuticals in 2023.
Read the Vistagen press release.
